When should anti‑thyroid peroxidase (anti‑TPO) and anti‑thyrotropin (TSH) receptor antibodies be measured?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Check Anti-TPO and Anti-TSH Receptor Antibodies

Check anti-TSH receptor antibodies (TRAb) first-line when thyrotoxicosis is confirmed to establish the diagnosis of Graves' disease, and measure anti-TPO antibodies in subclinical hypothyroidism to predict progression to overt disease.

Anti-TSH Receptor Antibodies (TRAb)

In Hyperthyroidism/Thyrotoxicosis

  • Order TRAb immediately when TSH is suppressed and free T4 is elevated to confirm Graves' disease 1
  • Modern TRAb assays have sensitivity and specificity approaching 100%, making them the definitive test for Graves' disease 1
  • If TRAb is positive, no additional etiologic testing (ultrasound, scintigraphy) is necessary in typical presentations (young female, homogeneous goiter, ophthalmopathy) 1
  • In atypical presentations, TRAb should be first-line alongside or instead of imaging 1

In Pregnancy - Critical Timing

Measure TRAb in pregnant women with current or past Graves' disease at specific gestational windows:

  • At 20-26 weeks gestation (or first trimester if elevated, then repeat at 20-26 weeks) in hypothyroid pregnant patients with history of Graves' disease treated with radioactive iodine or thyroidectomy 2
  • This timing is crucial because elevated TRAb predicts fetal/neonatal thyroid dysfunction with high correlation 2
  • At diagnosis if Graves' disease is identified during pregnancy, then repeat at 22-26 weeks if initially elevated 3
  • When etiology of hyperthyroidism in pregnancy is uncertain 3

The rationale: TRAb crosses the placenta and can cause fetal hyperthyroidism even in mothers who are hypothyroid after definitive treatment 2, 4.

Anti-TPO Antibodies

In Hypothyroidism

Measure anti-TPO when evaluating subclinical hypothyroidism (elevated TSH with normal free T4) 2

  • Anti-TPO positivity predicts progression to overt hypothyroidism at 4.3% per year versus 2.6% per year when negative 2, 5
  • This helps guide the decision to treat versus monitor, though the 2012 AACE/ATA guideline notes this is predictive rather than diagnostic, hence Grade B recommendation 2

Check anti-TPO when nodular thyroid disease is suspected to be due to autoimmune thyroiditis 2

In Reproductive Health

Measure anti-TPO in women with recurrent miscarriage, with or without infertility 2

  • This is a Grade A recommendation due to favorable risk-benefit potential 2
  • Anti-TPO positive women are at increased risk for progression of hypothyroidism and should be screened for TSH abnormalities before pregnancy and during first and second trimesters 6

In Confirmed Thyrotoxicosis with Negative TRAb

If TRAb is negative in a patient with confirmed thyrotoxicosis, measure anti-TPO to assess for autoimmune thyroiditis (Hashimoto's thyroiditis), which almost always shows positive anti-TPO 1

Algorithmic Approach

For Suspected Hyperthyroidism:

  1. Confirm with suppressed TSH + elevated free T4
  2. Order TRAb immediately for etiologic diagnosis
  3. If TRAb positive → Graves' disease confirmed
  4. If TRAb negative → Check anti-TPO to evaluate for autoimmune thyroiditis

For Subclinical Hypothyroidism:

  1. Confirm with elevated TSH (repeat in 2 weeks to 3 months) + normal free T4
  2. Measure anti-TPO to predict progression risk
  3. If TSH >10 mIU/L: stronger basis for treatment regardless of antibodies
  4. If TSH 4.5-10 mIU/L: anti-TPO helps guide treat-versus-monitor decision

For Pregnancy:

  1. History of Graves' disease (treated with RAI/thyroidectomy) → TRAb at 20-26 weeks (or first trimester then 20-26 weeks)
  2. Active Graves' disease in pregnancy → TRAb at diagnosis, repeat at 22-26 weeks if elevated
  3. Recurrent miscarriage/infertility → Anti-TPO before or early in pregnancy

Common Pitfalls

  • Don't routinely measure anti-TPO in all thyroid nodule patients unless nodular disease is suspected to be due to hypothyroidism 2, 7
  • Don't use anti-TPO to diagnose hypothyroidism - it only predicts risk of progression in subclinical disease 2
  • Don't delay TRAb measurement in pregnancy - the 20-26 week window is critical for assessing fetal risk 2, 3
  • Be aware of assay variability - anti-TPO thresholds range from 4-120 IU/L depending on the method 1
  • Don't order TRAb in typical Graves' disease if diagnosis is clinically obvious (young female, goiter, ophthalmopathy), though it can still be useful for treatment decisions 1

References

Guideline

diagnostic procedure in suspected graves' disease.

Annales d'endocrinologie, 2018

Guideline

clinical practice guidelines for hypothyroidism in adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2012

Guideline

hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Guideline

graves' disease and pregnancy.

Annales d'endocrinologie, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.